A Phase 3 interventional study of Adalimumab in Generalized Pustular Psoriasis (GPP), Adalimumab and Japanese, sponsored by AbbVie. Completed. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-14.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 46th largest by enrollment, is one of 3 that started in 2015, is one of 26 in phase 3, and was the 31st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 15 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 48th largest by enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2015, is one of 31 in phase 3, and was the 32nd registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.
This was a Phase 3, multicenter, open-label, single-arm study of adalimumab in Japanese participants with generalized pustular psoriasis (GPP). The study included a 30-day screening period, a 52-week treatment period, and a 70-day follow-up period. The dose regimen of adalimumab used in this study was 80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
Drug: Adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection
Also known as: Humira, ABT-D2E7
Proportion of Participants Achieving Clinical Response at Week 16
Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.
Time frame: Baseline and Week 16
Number of Participants Achieving Clinical Response Over Time
Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52
Number of Participants Achieving Clinical Remission Over Time
The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical remission was defined as a total skin score of 0.
Time frame: Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in the Total GPP Score Over Time
The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in JDA Severity Index of GPP Over Time
The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Total Skin Score Over Time
The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Percent Change From Baseline in Total Skin Score Over Time
The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Total Systemic/Laboratory Test Score Over Time
The Generalized Pustular Psoriasis (GPP) total systemic/laboratory test score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Total Erythema Area Over Time
The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema (redness) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 75%; moderate, ≥ 25% and \< 75%; mild, \< 25%); and none (0%). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Total Erythema Area With Pustules Over Time
The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema with pustules (small pockets of pus) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area with pustules is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Total Edema Area Over Time
The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of edema (swelling) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total area of edema is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Body Temperature Over Time
Body temperature (oral) was obtained at each visit prior to blood sampling.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in White Blood Cell (WBC) Concentration Over Time
Blood was drawn at each study visit, and white blood cell concentration was determined.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Over Time
Blood was drawn at each study visit, and high-sensitivity C-reactive protein (hs-CRP) concentration was determined.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Serum Albumin Over Time
Blood was drawn at each study visit, and serum albumin concentration was determined.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Number of Participants Achieving "Mild" in the JDA Severity Index of Generalized Pustular Psoriasis (GPP) for Participants With "Moderate" or "Severe" at Baseline Over Time
The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Achieving Treatment Success in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Over Time
The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number. Treatment Success was defined by at least a 2 grade improvement relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Change From Baseline in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade Over Time
The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Achieving Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade 0 or 1 for Those With PGA Grade of at Least 2 at Baseline Over Time
The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Achieving Psoriasis Area and Severity Index 90 (PASI 90) Over Time
The proportion of participants with a ≥ 90% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Over Time
The proportion of participants with a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Achieving Psoriasis Area and Severity Index 50 (PASI 50) Over Time
The proportion of participants with a ≥ 50% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time
The mean change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time
The percent change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 Over Time
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.
Time frame: Week 8, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 8, Week 16, Week 24, Week 36, Week 52
Mean Change From Baseline in Short Form-36 Health Status Survey Version 2 (SF-36 V2) Score Over Time
The Short Form-36 Health Status Survey Version 2 (SF-36 V2) is a 36-item generic health-related quality of life questionnaire to assess the participant's view of their health consisting of 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.
Time frame: Baseline, Week 8, Week 16, Week 24, Week 36, Week 52
Proportion of Participants Taking Systemic Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study
GPP-specific co-medications were documented at each scheduled study visit.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52
Proportion of Participants Taking Topical Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study
Participants using topical co-medications for GPP were documented at each scheduled study visit.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52
| Milestone | Participants Receiving Adalimumab |
|---|---|
| Started | 10 |
| Completed | 5 |
| Not completed | 5 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Adverse event | 2 |
Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Proportion of Participants Achieving Clinical Response at Week 16 | 7 |
Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.
| participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 5 |
| Week 4 | 6 |
| Week 8 | 6 |
| Week 12 | 5 |
| Week 24 | 6 |
| Week 36 | 6 |
| Week 52 | 5 |
The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical remission was defined as a total skin score of 0.
| participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 0 |
| Week 4 | 1 |
| Week 8 | 0 |
| Week 12 | 0 |
| Week 16 | 0 |
| Week 24 | 0 |
| Week 36 | 0 |
| Week 52 | 0 |
The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -2.9 ± 2.08 |
| Week 4 | -3.8 ± 2.15 |
| Week 8 | -3.2 ± 2.57 |
| Week 12 | -3.1 ± 2.85 |
| Week 16 | -4.6 ± 1.85 |
| Week 24 | -3.8 ± 3.15 |
| Week 36 | -5.5 ± 2.07 |
| Week 52 | -6.0 ± 2.55 |
The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Baseline — Mild | 3 |
| Baseline — Moderate | 6 |
| Baseline — Severe | 1 |
| Baseline — Missing | 0 |
| Week 2 — Mild | 7 |
| Week 2 — Moderate | 3 |
| Week 2 — Severe | 0 |
| Week 2 — Missing | 0 |
| Week 4 — Mild | 9 |
| Week 4 — Moderate | 1 |
| Week 4 — Severe | 0 |
| Week 4 — Missing | 0 |
| Week 8 — Mild | 8 |
| Week 8 — Moderate | 1 |
| Week 8 — Severe | 1 |
| Week 8 — Missing | 0 |
| Week 12 — Mild | 7 |
| Week 12 — Moderate | 0 |
| Week 12 — Severe | 1 |
| Week 12 — Missing | 2 |
| Week 16 — Mild | 7 |
| Week 16 — Moderate | 1 |
| Week 16 — Severe | 0 |
| Week 16 — Missing | 2 |
| Week 24 — Mild | 7 |
| Week 24 — Moderate | 0 |
| Week 24 — Severe | 1 |
| Week 24 — Missing | 2 |
| Week 36 — Mild | 6 |
| Week 36 — Moderate | 0 |
| Week 36 — Severe | 0 |
| Week 36 — Missing | 4 |
| Week 52 — Mild | 5 |
| Week 52 — Moderate | 0 |
| Week 52 — Severe | 0 |
| Week 52 — Missing | 5 |
The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -1.9 ± 1.66 |
| Week 4 | -2.4 ± 1.65 |
| Week 8 | -2.3 ± 1.49 |
| Week 12 | -2.3 ± 1.98 |
| Week 16 | -3.1 ± 1.36 |
| Week 24 | -2.6 ± 1.92 |
| Week 36 | -3.8 ± 1.47 |
| Week 52 | -4.2 ± 1.79 |
The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.
| percentage change from baseline | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -33.8 ± 27.71 |
| Week 4 | -43.4 ± 27.28 |
| Week 8 | -42.9 ± 27.12 |
| Week 12 | -39.9 ± 30.36 |
| Week 16 | -54.6 ± 20.77 |
| Week 24 | -46.6 ± 33.15 |
| Week 36 | -67.9 ± 13.58 |
| Week 52 | -72.3 ± 16.34 |
The Generalized Pustular Psoriasis (GPP) total systemic/laboratory test score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -1.0 ± 1.05 |
| Week 4 | -1.4 ± 0.97 |
| Week 8 | -0.9 ± 1.45 |
| Week 12 | -0.9 ± 1.25 |
| Week 16 | -1.5 ± 1.20 |
| Week 24 | -1.1 ± 1.64 |
| Week 36 | -1.7 ± 1.21 |
| Week 52 | -1.8 ± 1.30 |
The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema (redness) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 75%; moderate, ≥ 25% and \< 75%; mild, \< 25%); and none (0%). Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -17.0 ± 20.08 |
| Week 4 | -21.6 ± 22.81 |
| Week 8 | -19.7 ± 26.62 |
| Week 12 | -23.0 ± 26.28 |
| Week 16 | -34.6 ± 27.30 |
| Week 24 | -27.6 ± 29.48 |
| Week 36 | -48.3 ± 27.72 |
| Week 52 | -44.6 ± 37.50 |
The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema with pustules (small pockets of pus) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area with pustules is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -9.3 ± 8.96 |
| Week 4 | -11.7 ± 9.01 |
| Week 8 | -8.3 ± 11.42 |
| Week 12 | -8.3 ± 14.63 |
| Week 16 | -11.8 ± 10.65 |
| Week 24 | -7.1 ± 16.75 |
| Week 36 | -13.3 ± 12.44 |
| Week 52 | -14.8 ± 13.31 |
The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of edema (swelling) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total area of edema is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -9.1 ± 9.45 |
| Week 4 | -12.8 ± 11.29 |
| Week 8 | -12.4 ± 17.30 |
| Week 12 | -6.3 ± 31.96 |
| Week 16 | -15.4 ± 17.30 |
| Week 24 | -14.0 ± 17.72 |
| Week 36 | -21.2 ± 14.68 |
| Week 52 | -18.6 ± 14.31 |
Body temperature (oral) was obtained at each visit prior to blood sampling.
| degrees Celsius | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -0.3 ± 0.68 |
| Week 4 | -0.5 ± 0.52 |
| Week 8 | -0.3 ± 0.50 |
| Week 12 | -0.1 ± 0.64 |
| Week 16 | -0.3 ± 0.50 |
| Week 24 | -0.5 ± 1.04 |
| Week 36 | -0.3 ± 0.86 |
| Week 52 | -0.1 ± 0.64 |
Blood was drawn at each study visit, and white blood cell concentration was determined.
| cells/µL | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -1220.0 ± 1970.22 |
| Week 4 | -1770.0 ± 2572.96 |
| Week 8 | -810.0 ± 3104.28 |
| Week 12 | -1650.0 ± 2857.57 |
| Week 16 | -2562.5 ± 2960.18 |
| Week 24 | -1162.5 ± 4444.88 |
| Week 36 | -2550.0 ± 3229.09 |
| Week 52 | -2760.0 ± 2966.99 |
Blood was drawn at each study visit, and high-sensitivity C-reactive protein (hs-CRP) concentration was determined.
| mg/dL | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -1.5 ± 4.12 |
| Week 4 | -1.6 ± 4.05 |
| Week 8 | -0.3 ± 5.97 |
| Week 12 | -1.7 ± 4.76 |
| Week 16 | -2.5 ± 4.06 |
| Week 24 | -1.5 ± 5.63 |
| Week 36 | -2.7 ± 5.02 |
| Week 52 | -3.8 ± 4.73 |
Blood was drawn at each study visit, and serum albumin concentration was determined.
| g/dL | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 0.0 ± 0.33 |
| Week 4 | 0.1 ± 0.44 |
| Week 8 | 0.1 ± 0.38 |
| Week 12 | -0.2 ± 0.59 |
| Week 16 | -0.0 ± 0.39 |
| Week 24 | -0.0 ± 0.26 |
| Week 36 | -0.1 ± 0.54 |
| Week 52 | -0.0 ± 0.43 |
The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 4 |
| Week 4 | 6 |
| Week 8 | 5 |
| Week 12 | 5 |
| Week 16 | 5 |
| Week 24 | 5 |
| Week 36 | 5 |
| Week 52 | 4 |
The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number. Treatment Success was defined by at least a 2 grade improvement relative to baseline.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 3 |
| Week 4 | 5 |
| Week 8 | 4 |
| Week 12 | 3 |
| Week 16 | 5 |
| Week 24 | 4 |
| Week 36 | 5 |
| Week 52 | 3 |
The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Baseline — PGA Grade 0 | 0 |
| Baseline — PGA Grade 1 | 0 |
| Baseline — PGA Grade 2 | 4 |
| Baseline — PGA Grade 3 | 3 |
| Baseline — PGA Grade 4 | 3 |
| Baseline — PGA Grade 5 | 0 |
| Week 2 — PGA Grade 0 | 1 |
| Week 2 — PGA Grade 1 | 3 |
| Week 2 — PGA Grade 2 | 5 |
| Week 2 — PGA Grade 3 | 1 |
| Week 2 — PGA Grade 4 | 0 |
| Week 2 — PGA Grade 5 | 0 |
| Week 4 — PGA Grade 0 | 1 |
| Week 4 — PGA Grade 1 | 7 |
| Week 4 — PGA Grade 2 | 1 |
| Week 4 — PGA Grade 3 | 1 |
| Week 4 — PGA Grade 4 | 0 |
| Week 4 — PGA Grade 5 | 0 |
| Week 8 — PGA Grade 0 | 0 |
| Week 8 — PGA Grade 1 | 8 |
| Week 8 — PGA Grade 2 | 0 |
| Week 8 — PGA Grade 3 | 1 |
| Week 8 — PGA Grade 4 | 1 |
| Week 8 — PGA Grade 5 | 0 |
| Week 12 — PGA Grade 0 | 1 |
| Week 12 — PGA Grade 1 | 4 |
| Week 12 — PGA Grade 2 | 2 |
| Week 12 — PGA Grade 3 | 0 |
| Week 12 — PGA Grade 4 | 0 |
| Week 12 — PGA Grade 5 | 1 |
| Week 16 — PGA Grade 0 | 2 |
| Week 16 — PGA Grade 1 | 5 |
| Week 16 — PGA Grade 2 | 1 |
| Week 16 — PGA Grade 3 | 0 |
| Week 16 — PGA Grade 4 | 0 |
| Week 16 — PGA Grade 5 | 0 |
| Week 24 — PGA Grade 0 | 1 |
| Week 24 — PGA Grade 1 | 5 |
| Week 24 — PGA Grade 2 | 0 |
| Week 24 — PGA Grade 3 | 2 |
| Week 24 — PGA Grade 4 | 0 |
| Week 24 — PGA Grade 5 | 0 |
| Week 36 — PGA Grade 0 | 2 |
| Week 36 — PGA Grade 1 | 4 |
| Week 36 — PGA Grade 2 | 0 |
| Week 36 — PGA Grade 3 | 0 |
| Week 36 — PGA Grade 4 | 0 |
| Week 36 — PGA Grade 5 | 0 |
| Week 52 — PGA Grade 0 | 3 |
| Week 52 — PGA Grade 1 | 2 |
| Week 52 — PGA Grade 2 | 0 |
| Week 52 — PGA Grade 3 | 0 |
| Week 52 — PGA Grade 4 | 0 |
| Week 52 — PGA Grade 5 | 0 |
The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 4 |
| Week 4 | 8 |
| Week 8 | 8 |
| Week 12 | 5 |
| Week 16 | 7 |
| Week 24 | 6 |
| Week 36 | 6 |
| Week 52 | 5 |
The proportion of participants with a ≥ 90% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 1 |
| Week 4 | 2 |
| Week 8 | 1 |
| Week 12 | 1 |
| Week 16 | 0 |
| Week 24 | 1 |
| Week 36 | 3 |
| Week 52 | 3 |
The proportion of participants with a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 2 |
| Week 4 | 2 |
| Week 8 | 2 |
| Week 12 | 2 |
| Week 16 | 4 |
| Week 24 | 4 |
| Week 36 | 5 |
| Week 52 | 3 |
The proportion of participants with a ≥ 50% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 2 | 4 |
| Week 4 | 6 |
| Week 8 | 6 |
| Week 12 | 5 |
| Week 16 | 5 |
| Week 24 | 4 |
| Week 36 | 5 |
| Week 52 | 4 |
The mean change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -12.9 ± 12.83 |
| Week 4 | -17.4 ± 14.66 |
| Week 8 | -14.9 ± 17.55 |
| Week 12 | -14.3 ± 20.03 |
| Week 16 | -19.1 ± 17.27 |
| Week 24 | -16.8 ± 19.61 |
| Week 36 | -28.1 ± 17.67 |
| Week 52 | -26.7 ± 22.24 |
The percent change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.
| percentage change from baseline | Participants Receiving Adalimumab |
|---|---|
| Week 2 | -44.2 ± 27.47 |
| Week 4 | -59.7 ± 24.65 |
| Week 8 | -43.9 ± 45.01 |
| Week 12 | -45.0 ± 39.20 |
| Week 16 | -55.5 ± 31.89 |
| Week 24 | -43.6 ± 46.26 |
| Week 36 | -79.0 ± 24.13 |
| Week 52 | -33.7 ± 117.4 |
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Week 8 | 1 |
| Week 16 | 0 |
| Week 24 | 1 |
| Week 36 | 0 |
| Week 52 | 2 |
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Negative values indicate improvement from baseline.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Week 8 | -4.2 ± 6.55 |
| Week 16 | -6.6 ± 5.34 |
| Week 24 | -4.8 ± 7.59 |
| Week 36 | -6.5 ± 5.65 |
| Week 52 | -8.0 ± 7.18 |
The Short Form-36 Health Status Survey Version 2 (SF-36 V2) is a 36-item generic health-related quality of life questionnaire to assess the participant's view of their health consisting of 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.
| units on a scale | Participants Receiving Adalimumab |
|---|---|
| Physical Component Summary- Week 8 | 4.7 ± 19.05 |
| Physical Component Summary- Week 16 | 9.2 ± 17.48 |
| Physical Component Summary- Week 24 | 8.2 ± 15.94 |
| Physical Component Summary- Week 36 | 4.9 ± 23.39 |
| Physical Component Summary- Week 52 | 12.0 ± 21.42 |
| Mental Component Summary- Week 8 | 0.6 ± 8.71 |
| Mental Component Summary- Week 16 | 0.9 ± 8.03 |
| Mental Component Summary- Week 24 | 2.0 ± 8.32 |
| Mental Component Summary- Week 36 | 1.6 ± 18.26 |
| Mental Component Summary- Week 52 | 6.4 ± 7.79 |
GPP-specific co-medications were documented at each scheduled study visit.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Etretinate | 3 |
| Methotrexate | 2 |
| Oral steroids | 1 |
| Cyclosporine | 2 |
Participants using topical co-medications for GPP were documented at each scheduled study visit.
| Participants | Participants Receiving Adalimumab |
|---|---|
| Corticosteroid | 7 |
| Vitamin D3 | 0 |
| Tacrolimus | 0 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 70 days after the last dose of study drug (up to 62 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Receiving Adalimumab | 0/10 (0%) | 3/10 (30%) | 9/10 (90%) |
| Event | Participants Receiving Adalimumab |
|---|---|
| Cardiac failureCardiac disorders | 1/10 |
| Chronic sinusitisInfections and infestations | 1/10 |
| Enterocolitis bacterialInfections and infestations | 1/10 |
| DehydrationMetabolism and nutrition disorders | 1/10 |
| Renal failureRenal and urinary disorders | 1/10 |
| Pustular psoriasisSkin and subcutaneous tissue disorders | 1/10 |
| Event | Participants Receiving Adalimumab |
|---|---|
| NasopharyngitisInfections and infestations | 3/10 |
| PruritusSkin and subcutaneous tissue disorders | 3/10 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/10 |
| EosinophiliaBlood and lymphatic system disorders | 1/10 |
| Cardiac failureCardiac disorders | 1/10 |
| Autoimmune ThyroiditisEndocrine disorders | 1/10 |
| Dry eyeEye disorders | 1/10 |
| EpiscleritisEye disorders | 1/10 |
| GlaucomaEye disorders | 1/10 |
| Abdominal painGastrointestinal disorders | 1/10 |
Full Analysis Set (FAS): all participants who received at least 1 dose of study drug and had at least 1 post-treatment efficacy assessment.
| Age, Continuous(years) | Participants Receiving Adalimumab |
|---|---|
| Mean | 49.8 ± 13.26 |
| Sex: Female, Male(Participants) | Participants Receiving Adalimumab |
|---|---|
| Female | 3 |
| Male | 7 |
| Race (NIH/OMB)(Participants) | Participants Receiving Adalimumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Generalized Pustular Psoriasis (GPP) Duration(years) | Participants Receiving Adalimumab |
|---|---|
| Mean | 10.6 ± 12.59 |
| Prior GPP Therapy(Participants) | Participants Receiving Adalimumab |
|---|---|
| Psoralen and ultraviolet A light (PUVA) | 1 |
| Narrow-band ultraviolet B light (UVB) | 2 |
| Granulocyte and Monocyte Absorbent Apheresis (GMA) | 2 |
| None of the above | 5 |
| Prior Infliximab Use(Participants) | Participants Receiving Adalimumab |
|---|---|
| Yes | 3 |
| No | 7 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Sep 2015, a primary completion of Sep 2016 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab